Physician profile
Robert K Oldham
NPI 1548255334
$1,130.50
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $316 · 2021: $246 · 2022: $85.15.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $184.16 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $114.16 | 2019 | |
| Merck Sharp & Dohme LLC | $110.93 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $82.13 | 2019-2020 | |
| Genentech USA, INC. | $77.02 | 2019 | |
| Amgen INC. | $67.98 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $48.69 | 2021 | |
| Abbvie INC. | $46.22 | 2021-2022 | |
| Eisai INC. | $39.92 | 2021 | |
| Genentech, INC. | $38.00 | 2019 | |
| Rigel Pharmaceuticals, INC. | $34.25 | 2019-2020 | |
| Genzyme Corporation | $32.43 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $30.54 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $27.89 | 2020 | |
| Pfizer INC. | $24.74 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $24.18 | 2020 | |
| Beigene USA, INC. | $22.52 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.28 | 2021 | |
| Incyte Corporation | $16.53 | 2021 | |
| Karyopharm Therapeutics INC. | $15.08 | 2020 | |
| Clovis Oncology, INC. | $14.89 | 2020 | |
| Coherus Oncology, INC. | $13.00 | 2021 | |
| Lilly USA, LLC | $12.89 | 2019 | |
| Puma Biotechnology, INC. | $12.55 | 2020 | |
| Deciphera Pharmaceuticals INC. | $11.38 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $11.14 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Oldham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.